CeriBell (CBLL) to Release Quarterly Earnings on Tuesday

CeriBell (NASDAQ:CBLL - Get Free Report) is projected to issue its quarterly earnings data after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $17.55 million for the quarter. Parties interested in listening to the company's conference call can do so using this link.

CeriBell Stock Performance

Shares of CeriBell stock traded up $1.58 during trading on Friday, hitting $24.69. 320,260 shares of the company's stock traded hands, compared to its average volume of 135,595. The business's fifty day simple moving average is $23.53. CeriBell has a twelve month low of $18.69 and a twelve month high of $32.75.

Analysts Set New Price Targets

CBLL has been the topic of several recent research reports. TD Cowen lifted their target price on shares of CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Canaccord Genuity Group lifted their target price on shares of CeriBell from $31.00 to $33.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Canaccord Genuity Group initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a "buy" rating and a $30.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an "overweight" rating and a $32.00 target price on the stock. Finally, William Blair initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an "outperform" rating on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CeriBell currently has a consensus rating of "Buy" and an average price target of $32.60.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.